Primary Sjogren syndrome is a chronic inflammatory disorder associated with lymphocytic infiltration of exocrine glands. The infiltrate is composed mainly of T lymphocytes, though in some salivary biopsies non-T/non-B lymphocytes predominate. The lymphocytic infiltration is progressive and the infiltrating lymphocytes are retained and persist in the exocrine glands. Several autoantibodies have been shown to be associated with Sjogren syndrome (SS) (including rheumatoid factor, anti-SS-A, and anti-SS-B). The disease is not associated with any cellular proliferative responses to self antigens. Hence there is no explanation as to what keeps the infiltrating lymphocytes in the glands. Several viruses have been proposed as triggers of the autoimmune response. The mechanisms involved in the retention of infiltrating lymphocytes in the glands may involve changes in the pattern or density of adhesion molecule expression. Another possibility is the presence of follicular dendritic cells (FDC) which may functionally maintain the lymphocytes in lymphoid follicles, as seen in the salivary or lacrimal glands of these patients. The aim of this study was to compare the phenotypic characteristics of FDC in labial salivary glands of patients with primary Sjogren syndrome and those seen in tonsillar lymphoid follicles, as an example of organised peripheral lymphoid tissue. This may increase our understanding of Sjogren syndrome.

The origins of dendritic cells are not completely clear. Dendritic cells can form clusters with T or B lymphocytes. They may stimulate autologous and alloimmune mixed lymphocyte reactions. They are powerful accessory cells and can induce the expression of activation antigens by lymphocytes. Dendritic cells are situated in close proximity to lymphocytes in lymphoid organs. This rendered the determination of their antigenic phenotype difficult. There is no accepted classification of dendritic cells, and most classifications describe a phenotypic and functional overlap between different types of dendritic cell. CD35 (DRC-1) may be expressed on all dendritic cells in lymphoid tissues, and Schriefer et al isolated unclustered FDC and phenotypically characterised these cells. They reported that FDC express several complement receptors (CR), namely CR1 (CD35), CR2 (CD21), CR3 (CD11b), and the myeloid/monocytic cell marker CD14. Another group showed that isolated FDC lack the expression of CD35. This may be due to the isolation of a different subpopulation of dendritic cells from the same lymphoid organ resulting from variable origins of the dendritic cells, variable stages of maturation, or functional alteration of these cells in different physiological or pathological situations.

VLA-2a and VLA-3a are integrin molecules that may be expressed by FDC and they have a common β chain CD29. The ligands for VLA-2a and VLA-3a are laminin, collagen, and fibronectin.
Methods

SUBJECTS
Fifteen patients with primary Sjogren syndrome fulfilling at least five (a minimum of four is required) of the European Community criteria were the subjects of this study. Patients ranged in age from 24 to 87 years, with a mean of 50.4 years. There were 14 females and one male. A positive Schirmer test was demonstrated in 11 patients (73%) and a positive Rose Bengal test in 14 (93%). Abnormal unstimulated salivary flow rates (< 0.1 ml min⁻¹) were found in 12 patients (80%). Rheumatoid factor was detected in 12 patients (80%), anti-nuclear antibodies (ANA) in 11 (73%), and anti-SS-A and/or anti-SS-B in nine (60%). Serum anti-ds-DNA was not detected (73%), and anti-SS-A and/or anti-SS-B in nine (60%). Serum anti-ds-DNA was not detected.

LABIAL SALIVARY GLAND BIOPSY
The technique used for obtaining labial salivary glands from patients was based on previously described methods. Labial salivary gland and tonsil specimens were transferred in normal saline (0.9% NaCl) to be used for immunohistology. The biopsies were embedded in OCT compound (Bayer, Miles Laboratories), snap frozen, and cryostat sections 4 microns thick were cut. The sections were fixed in cold (2-4°C) acetone for five minutes followed by phosphate buffered saline (PBS) for five minutes (repeated twice in PBS). Sections were stored at −70°C.

IMMUNOHISTOCHEMISTRY
An indirect immunoperoxidase technique was used as described before. The specificities and dilutions of the monoclonal antibodies which were used as primary antibodies are listed in table 1.

<table>
<thead>
<tr>
<th>Antigen/specificity</th>
<th>Clone</th>
<th>Ig chain</th>
<th>Supplier</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dendritic cell markers:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD11b (CD18)</td>
<td>4B4LDQ9LDH8</td>
<td>IgG</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD49b (a2, VLA-2 a)</td>
<td>P1E6</td>
<td>IgG1</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD35 (CR1, DRC-1)</td>
<td>Ber-MAC-DRC</td>
<td>IgG</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11a (CD18)</td>
<td>MMH23</td>
<td>IgG1</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11c (a4, VLA-3 a)</td>
<td>2LPM19c</td>
<td>IgG1</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11b (aM, C3biR a)</td>
<td>SHCL3</td>
<td>IgG2b</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11c (aX, p150.95)</td>
<td>P1E6</td>
<td>IgG1</td>
<td>Dako or Immunotech</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11a (CD18)</td>
<td>SHCL3</td>
<td>IgG1</td>
<td>Dako or Immunotech</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11b (aM, C3biR a)</td>
<td>2LPM19c</td>
<td>IgG1</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11c (aX, p150.95)</td>
<td>P1E6</td>
<td>IgG1</td>
<td>Dako or Immunotech</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11b (aM, C3biR a)</td>
<td>2LPM19c</td>
<td>IgG1</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11c (aX, p150.95)</td>
<td>P1E6</td>
<td>IgG1</td>
<td>Dako or Immunotech</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11b (aM, C3biR a)</td>
<td>2LPM19c</td>
<td>IgG1</td>
<td>Dako</td>
<td>1/50</td>
</tr>
<tr>
<td>CD11c (aX, p150.95)</td>
<td>P1E6</td>
<td>IgG1</td>
<td>Dako or Immunotech</td>
<td>1/50</td>
</tr>
</tbody>
</table>

MICROSCOPIC EXAMINATION OF SECTIONS
Sections were examined with light microscopy using a Microphot FX microscope (Nikon, Japan). Labial salivary gland sections were examined for positive staining as indicated by the brown colour developed by the specific immunohistochemical reaction. Follicular dendritic cells were localised as shown by positive staining with CD35 (DRC-1), CD106 (VCAM-1), and their characteristic dendritic morphology. Other cellular elements staining with each antibody were recorded.

Results

EXPRESSION OF DENDRITIC CELL MARKERS BY FDC IN LABIAL SALIVARY GLANDS OF PATIENTS WITH PRIMARY SJOGREN SYNDROME
FDC in labial salivary glands of patients with primary Sjogren syndrome expressed CD35 (DRC-1) to the same extent as in tonsillar sections (figure, A, B, table 2). VLA-2α (CD49b) and VLA-3α (CD49c) were not expressed by follicular dendritic cells in labial salivary glands of patients with Sjogren syndrome (table 2), while FDC (in situ) in lymphoid follicles of tonsils expressed both VLA-2α and VLA-3α strongly, although at a lesser intensity than CD35 or CD11c (figure, C, D, table 2). FDC in labial salivary glands and tonsils expressed CD29 (β1 integrin), the β chain for VLA-1, -2, -3, -4, -5, and -6 molecules. Acinar and ductal epithelial cells in labial salivary glands of patients with primary Sjogren syndrome expressed both VLA-2α and VLA-3α (figure, D). Similarly, stratified squamous epithelial cells in tonsils expressed both antigens. VCAM-1 was detectable at a variable intensity (from one follicle to another) on FDC in labial salivary glands of patients with primary Sjogren syndrome (figure, H) and in tonsils (table 2). CD11c was strongly expressed by FDC both from labial salivary glands of patients and from tonsils (figure, F, G). Neither CD11b nor CD14 was identifiable on dendritic cells in labial salivary glands of patients with primary Sjogren syndrome. FDC in tonsillar lymphoid follicles expressed CD11b and CD14 (figure, E). Although this study shows the expression of CD35, CD11b, and CD14 on FDC in tonsils, it cannot be
confirm that all dendritic cells in tonsillar lymphoid follicles expressed these markers. Class I and class II major histocompatibility complex (MHC) expression was demonstrated on FDC of patients with primary Sjogren syndrome and on tonsils (table 2). CD11a (αL integrin), CD18 (β2 integrin), and their ligand ICAM-1 were also strongly expressed by FDC in labial salivary glands and tonsils (table 2).

Follicular dendritic cells were identified in a considerable proportion of lymphoid follicles present in labial salivary glands of patients with primary Sjogren syndrome. The percentage of lymphoid follicles that have detectable follicular dendritic cells ranged from 29% to 100% of follicles in labial salivary glands. The majority of labial salivary glands contained FDC in more than 50% [mean (SEM) 74.7 (5.9) %] of the lymphoid follicles present. Tonsil sections showed FDC in 99% of lymphoid follicles. FDC were sometimes seen in small lymphoid aggregates not forming follicles. FDC were not seen adjacent to glandular epithelium or epimyoepithelial islands.

Frozen sections of labial salivary glands of patients with primary Sjogren syndrome and tonsils examined by an indirect immunoperoxidase technique yielding a brown colour which appears as dark shadows in the photomicrographs. (A) Follicular dendritic cells and lymphocytes in the germinal centre (large arrow) of a tonsillar lymphoid follicle intensely express CD35 (×225). (B) Several dendritic cells in that lymphoid follicle (large arrow) in a labial salivary gland express CD35 (×225). (C) Tonsillar dendritic cells (arrow heads) express VLA-2α in the germinal centre (×113). (D) A lymphoid focus (large arrows) shows the absence of VLA-2α while ductal (arrows), acinar epithelial cells, and endothelial cells (arrow head) intensely expressed that molecule in labial salivary glands of a patient with primary Sjogren syndrome (×225). That lymphoid focus contained dendritic cells that expressed CD35 and VCAM-1. (E) Dendritic cells express CD11b in tonsils (×225). (F) Dendritic cells (arrow heads) in tonsillar lymphoid follicles intensely express CD11c in that germinal centre (×225). (G) Several dendritic cells (arrow heads) in a lymphoid focus in labial salivary glands of a patient with primary Sjogren syndrome express distinctly CD11c (×225). (H) A lymphoid follicle in labial salivary gland shows VCAM-1 expression by dendritic cells (arrows) (×225).
Characterisation of salivary follicular dendritic cells in Sjogren syndrome

Table 2  Expression of different dendritic cell markers by follicular dendritic cells (FDC) in labial salivary glands (LSG) of patients with Sjogren syndrome and tonsillar lymphoid follicles

<table>
<thead>
<tr>
<th>Marker</th>
<th>FDC, LSG, Sjogren syndrome</th>
<th>FDC, tonsils</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD35 (DRC1)</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>CD29 (VLA-f)</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>CD40b (VLA-2a)</td>
<td>−, detectable on few cells with dendritic cell morphology; +, detectable on a proportion of dendritic cells; ++, detectable on the majority (≥ 50%) of follicular dendritic cells; ++++, detectable on almost all follicular dendritic cells.</td>
<td></td>
</tr>
<tr>
<td>CD40c (VLA-3a)</td>
<td>Negative</td>
<td>+</td>
</tr>
<tr>
<td>CD18</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>CD11a</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>CD11c (p150.95)</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CD11b (C3biR)</td>
<td>(+/-)</td>
<td>+</td>
</tr>
<tr>
<td>VCAM-1 (CD106)</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
| CD29 (VLA-
| CD54 (ICAM-1) | +++ | +++ |
| Class I MHC | + | + |
| Class II MHC (DR) | + | + |
| CD54 (ICAM-1) | +++ | +++ |

Grades: Negative, not detectable; +, detectable on few cells with dendritic cell morphology; +, detectable on a proportion of dendritic cells; ++, detectable on the majority (≥ 50%) of follicular dendritic cells; ++++, detectable on almost all follicular dendritic cells.

Discussion

In this study we showed that FDC were present in lymphoid follicles in labial salivary glands from patients with primary Sjogren syndrome. The expression of CD11c by these FDC may be important. Blocking CD11c has been shown to decrease the stimulatory effect of dendritic cells on T cell proliferation.16 CD11c is expressed by blood dendritic cells14 and tonsillar FDC. The lack of expression of the myeloid markers CD14 and CD11b by FDC in labial salivary glands of patients with Sjogren syndrome indicates that these cells are more mature and may have more efficient accessory functions, as shown by blood dendritic cells that do not express these markers.15 This may also indicate that the dendritic cells in labial salivary glands of patients with Sjogren syndrome may not be of myeloid origin. Different origins for FDC have been proposed, including myeloid or lymphoid progenitors.10,14,15 The expression of lymphoid markers, such as CD3, or in some foci CD19, by lymphocytes in the close proximity of dendritic cells makes definitive determination of the expression of these markers by the dendritic cells themselves difficult. Separation of the dendritic cells may allow more satisfactory examination of their phenotypic and functional characteristics, though the small size of the biopsies and small number of dendritic cells present will limit the feasibility of such an in vitro approach. Another interesting finding is the lack of expression of VLA-2α and VLA-3α by FDC in labial salivary glands of patients.15,16 Although FDC in labial salivary glands and tonsils express VCAM-1, blood dendritic cells do not express this molecule.18 If these dendritic cells originated from the blood, they may have acquired VCAM-1 and increased CD11c expression in the local autoimmune lesions in labial salivary glands of patients with Sjogren syndrome.

The results of this study show that dendritic cells are present in labial salivary glands of patients with Sjogren syndrome. They may play an important role in regulating immune responses and the retention of infiltrating lymphocytes in the glands. Although the origin of these dendritic cells is not clear, their phenotypic characteristics suggest that they may have originated from non-myeloid blood dendritic cells. Blood dendritic cells can bind to a number of adhesion molecules19,20 that are expressed on endothelial cells in labial salivary glands of patients with Sjogren syndrome2 and this may provide a portal of entry into the glands.

Characterisation of follicular dendritic cells in labial salivary glands of patients with primary Sjogren syndrome: comparison with tonsillar lymphoid follicles

Karim Elias Aziz, Peter J McCluskey and Denis Wakefield

*Ann Rheum Dis* 1997 56: 140-143
doi: 10.1136/ard.56.2.140

Updated information and services can be found at:
http://ard.bmj.com/content/56/2/140

These include:

**References**

This article cites 18 articles, 6 of which you can access for free at:
http://ard.bmj.com/content/56/2/140#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Ophthalmology (128)
- Rheumatoid arthritis (3258)
- Pathology (444)
- Clinical diagnostic tests (1282)
- Radiology (1113)
- Surgical diagnostic tests (431)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/